{"id":"NCT00894647","sponsor":"Graceway Pharmaceuticals, LLC","briefTitle":"Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery","officialTitle":"A Phase 3b Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2009-05-07","resultsPosted":"2010-08-23","lastUpdate":"2010-08-31"},"enrollment":247,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"imiquimod cream","otherNames":[]},{"type":"DRUG","name":"placebo cream","otherNames":[]}],"arms":[{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"imiquimod cream","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).","primaryOutcome":{"measure":"Change From Baseline in Percentage of Lesion Count","timeFrame":"Week 26","effectByArm":[{"arm":"Placebo Cream","deltaMin":-43.3,"sd":30.66},{"arm":"Imiquimod Cream","deltaMin":-77.4,"sd":27.54}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":18,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":121},"commonTop":["Upper respiratory tract infection","Application site pruritus","Application site irritation","Myalgia","Nausea"]}}